SCHEMBL19971393

SCHEMBL19971393

CCC(C)(CC)NC(=O)c1cn(-c2c(F)cc(F)cc2F)c2nc(N3C[C@@H](O)[C@H](O)C3)c(F)cc2c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
HSD17B10 Q99714 4/20 0.46
LMNA P02545 3/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 3/20 0.46
POLB P06746 1/20 0.46
XBP1 P17861 1/20 0.46
NFKB1 P19838 1/20 0.46
HTT P42858 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
EPHA2 P29317 1/20 0.46
FLT4 P35916 1/20 0.46
GSK3B P49841 1/20 0.46
RARB P10826 1/20 0.46
TBXAS1 P24557 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KMT2A Q03164 2/20 0.42
CYP2C9 P11712 2/20 0.39
ATP6V1B2 P21281 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19987020 1.00 KDM4E (0.46) KDM4EHSD17B10LMNAALDH1A1HPGD
SCHEMBL19986888 0.95 KDM4E (0.43) KDM4EHSD17B10LMNAALDH1A1HPGD
SCHEMBL19971457 0.93 KDM4E (0.46) KDM4EHSD17B10LMNAALDH1A1HPGD
SCHEMBL21309203 0.93 KDM4E (0.46) KDM4EHSD17B10LMNAALDH1A1HPGD
SCHEMBL19987101 0.93 KDM4E (0.46) KDM4EHSD17B10LMNAALDH1A1HPGD
SCHEMBL19971438 0.93 KDM4E (0.46) KDM4EHSD17B10LMNAALDH1A1HPGD
SCHEMBL19971375 0.92 KDM4E (0.48) KDM4EHSD17B10LMNAALDH1A1HPGD
SCHEMBL19971452 0.92 KDM4E (0.48) KDM4EHSD17B10LMNAALDH1A1HPGD
SCHEMBL19971479 0.91 LMNA (0.48) KDM4EHSD17B10LMNAALDH1A1HPGD
SCHEMBL19971406 0.91 LMNA (0.48) KDM4EHSD17B10LMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115554294-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2023-01-03 CN disclosed
CN-115477649-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-12-16 CN disclosed
CN-115429798-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-12-06 CN disclosed
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2022-10-18 US disclosed
CN-109689656-B 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-10-04 CN disclosed
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2022-03-24 US disclosed
EP-3512849-B1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE BAYER AG (DE) 2021-06-23 EP disclosed
EP-3512849-B1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE BAYER AG (DE) 2021-06-23 EP disclosed
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-02-23 US disclosed
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-02-23 US disclosed
US-20190263805-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2019-08-29 US disclosed
US-20190263805-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2019-08-29 US disclosed
EP-3296298-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE Bayer Pharma Aktiengesellschaft (DE) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263805-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF AADAC, GLS, NAT1 KDM4E 3765/4885HSD17B10 1808/4885LMNA 310/4885
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF AADAC, GLS, NAT1 KDM4E 3765/4885HSD17B10 1808/4885LMNA 310/4885
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof AADAC, GLS, NAT1 KDM4E 3765/4885HSD17B10 1808/4885LMNA 310/4885
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof AADAC, GLS, NAT1 KDM4E 3765/4885HSD17B10 1808/4885LMNA 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.